Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib plus intensive chemotherapy or azacitidine in previously untreated acute myeloid leukemia
2017-002822-19Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glasdegib in acute myeloid leukemia (AML) (4 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Feb 2018; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-002822-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002822-19.